Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Acurx Pharmaceuticals News

Aktie
WKN:  A41DXH ISIN:  US00510M2035 US-Symbol:  ACXP Branche:  Professionelle Dienstleistungen Land:  USA
2,53 $
+0,04 $
+1,61%
2,1386 € 15:46:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
2,29 Mio. €
Streubesitz
70,54%
KGV
-
Index-Zuordnung
-

Acurx Pharmaceuticals News

16.04.26 - PR Newswire
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
16.04.26 - PR Newswire
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-​The-Market Under Nasdaq Rules PR Newswire
30.03.26 - PR Newswire
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire
13.03.26 - PR Newswire
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update PR Newswire
09.03.26 - PR Newswire
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile ...
16.02.26 - PR Newswire
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update PR Newswire
02.02.26 - PR Newswire
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire
18.11.25 - PR Newswire
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals PR Newswire
12.11.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update PR Newswire
10.11.25 - PR Newswire
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-​positive Priority Pathogens PR Newswire
28.10.25 - PR Newswire
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific ...
27.10.25 - PR Newswire
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update PR Newswire
09.10.25 - PR Newswire
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors PR Newswire
30.09.25 - PR Newswire
Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection PR Newswire
03.09.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules PR Newswire
12.08.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update PR Newswire
31.07.25 - PR Newswire
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split PR Newswire
17.06.25 - PR Newswire
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire
17.06.25 - PR Newswire
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI PR Newswire
09.06.25 - PR Newswire
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-​Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of ...

Newssuche

Videos

newspaper
16.04.26 +0,31%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »